The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies

Resistance to proteasome inhibitors and other targeted therapies in myeloma

(2018) Craig T. Wallington-Beddoe et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cell-surface proteomics for the identification of novel therapeutic targets in cancer

(2018) Laura Kuhlmann et al.   Expert Review of Proteomics

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility

(2018) Irena Misiewicz-Krzeminska et al.   HAEMATOLOGICA

Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing

(2018) Georgina L Ryland et al.   JOURNAL OF CLINICAL PATHOLOGY

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma

(2018) Zhihong Zheng et al.   Journal of Hematology & Oncology

Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells

(2018) Vidya Ramakrishnan et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies

(2018) Martin Dom et al.   Journal of Proteomics

Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms

(2018) Phuc H. Hoang et al.   LEUKEMIA

Multiple myeloma clonal evolution in homogeneously treated patients

(2018) Jill Corre et al.   LEUKEMIA

Spectrum and functional validation of PSMB5 mutations in multiple myeloma

(2018) Santiago Barrio et al.   LEUKEMIA

A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity

(2018) Jiye Liu et al.   LEUKEMIA

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity

(2018) Nikoletta Lendvai et al.   LEUKEMIA & LYMPHOMA

MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment

(2018) Ola Landgren et al.   SEMINARS IN HEMATOLOGY

Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease

(2018) Katie L. Thoren   SEMINARS IN HEMATOLOGY

Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma

(2018) S. Manier et al.   Nature Communications

EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes

(2018) Taylor Harding et al.   Oncotarget

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility

(2018) Irena Misiewicz-Krzeminska et al.   HAEMATOLOGICA

A Challenge to Aging Society by microRNA in Extracellular Vesicles: microRNA in Extracellular Vesicles as Promising Biomarkers and Novel Therapeutic Targets in Multiple Myeloma

(2018) Tomofumi Yamamoto et al.   Journal of Clinical Medicine

Standardisation of minimal residual disease in multiple myeloma

(2017) V. Innao et al.   EUROPEAN JOURNAL OF CANCER CARE

Monitoring multiple myeloma by quantification of recurrent mutations in serum

(2017) Even Holth Rustad et al.   HAEMATOLOGICA

Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma

(2017) Seung-Hyun Jung et al.   HAEMATOLOGICA

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Ana

(2017) Neeraj Gupta et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Role of epigenetics-microRNA axis in drug resistance of multiple myeloma

(2017) Nasrin Rastgoo et al.   Journal of Hematology & Oncology

A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

(2017) Cristina Jiménez et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

(2017) A Besse et al.   LEUKEMIA

Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’

(2017) Matthew Ho Zhi Guang et al.   LEUKEMIA & LYMPHOMA

Therapy for Relapsed Multiple Myeloma

(2017) David Dingli et al.   MAYO CLINIC PROCEEDINGS

Comparative Analysis of Single-Cell RNA Sequencing Methods

(2017) Christoph Ziegenhain et al.   MOLECULAR CELL

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner

(2017) Konstantinos Dimopoulos et al.   Molecular Oncology

Precision medicine needs randomized clinical trials

(2017) Everardo D. Saad et al.   Nature Reviews Clinical Oncology

Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics

(2017) Andreas A. Argyriou et al.   Nature Reviews Neurology

Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell

(2017) Alboukadel Kassambara et al.   NUCLEIC ACIDS RESEARCH

Epigenetics in multiple myeloma: From mechanisms to therapy

(2017) Mohammad Alzrigat et al.   SEMINARS IN CANCER BIOLOGY

BAFF is involved in macrophage-induced bortezomib resistance in myeloma

(2017) Jing Chen et al.   Cell Death & Disease

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

(2017) L. Rasche et al.   Nature Communications

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates

(2017) Olena Kis et al.   Nature Communications

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma

(2017) A K Mitra et al.   Blood Cancer Journal

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine

(2017) Chantal Pauli et al.   Cancer Discovery

Coregulator profiling of the glucocorticoid receptor in lymphoid malignancies

(2017) Dorien Clarisse et al.   Oncotarget

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma

(2017) Yuji Mishima et al.   Cell Reports

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma

(2017) Mark E. Issa et al.   Clinical Epigenetics

Monitoring multiple myeloma by quantification of recurrent mutations in serum

(2017) Even Holth Rustad et al.   HAEMATOLOGICA

Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma

(2017) Seung-Hyun Jung et al.   HAEMATOLOGICA

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study

(2017) Berend Snijder et al.   Lancet Haematology

Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials

(2017) Manisha Bhutani et al.   Lancet Haematology

Multiple myeloma

(2017) Shaji K. Kumar et al.   Nature Reviews Disease Primers

Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma

(2017) Allison E. Drew et al.   Scientific Reports

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

(2016) Y.-T. Tai et al.   BLOOD

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma

(2016) N. Weinhold et al.   BLOOD

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

(2016) Inger S. Nijhof et al.   BLOOD

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

(2016) K. M. Kortum et al.   BLOOD

Daratumumab: First Global Approval

(2016) Kate McKeage   DRUGS

Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma

(2016) Nagaraju Anreddy et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance

(2016) Salvador Alonso et al.   JOURNAL OF CLINICAL INVESTIGATION

Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression

(2016) Jinheng Wang et al.   JOURNAL OF PATHOLOGY

Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers

(2016) Sean W. Harshman et al.   Journal of Proteomics

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma

(2016) S Mithraprabhu et al.   LEUKEMIA

Differentiation stage of myeloma plasma cells: biological and clinical significance

(2016) B Paiva et al.   LEUKEMIA

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

(2016) G P Soriano et al.   LEUKEMIA

Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry

(2016) Linda B. Baughn et al.   LEUKEMIA & LYMPHOMA

Genomic complexity of multiple myeloma and its clinical implications

(2016) Salomon Manier et al.   Nature Reviews Clinical Oncology

Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci

(2016) Chiara Campo et al.   NEUROCHEMICAL RESEARCH

Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade

(2016) Marco Alessandrini et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

Genetic interrogation of circulating multiple myeloma cells at single-cell resolution

(2016) J. G. Lohr et al.   Science Translational Medicine

A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma

(2016) N Bolli et al.   Blood Cancer Journal

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy

(2016) Dominik Dytfeld et al.   Oncotarget

The novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo

(2016) Gabriela Rozic et al.   Oncotarget

Microenvironment drug resistance in multiple myeloma: emerging new players

(2016) Lucia Di Marzo et al.   Oncotarget

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies

(2015) L. F. Peterson et al.   BLOOD

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy

(2015) S. Walz et al.   BLOOD

Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment

(2015) Alfred Adomako et al.   BMC CANCER

Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens

(2015) Dominik Dytfeld et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma

(2015) Y. Yang et al.   CANCER RESEARCH

Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma

(2015) P. Maiso et al.   CANCER RESEARCH

MicroC3: an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells

(2015) Chorom Pak et al.   Integrative Biology

The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma

(2015) Bingzong Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

(2015) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

(2015) Brian A. Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities

(2015) G. Shay et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors

(2015) A K Mitra et al.   LEUKEMIA

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

(2015) I S Nijhof et al.   LEUKEMIA

Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma

(2015) M B Meads et al.   ONCOGENE

Characterizing noise structure in single-cell RNA-seq distinguishes genuine from technical stochastic allelic expression

(2015) Jong Kyoung Kim et al.   Nature Communications

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma

(2015) T Vu et al.   Blood Cancer Journal

Interpretation of cytogenetic results in multiple myeloma for clinical practice

(2015) A M Rajan et al.   Blood Cancer Journal

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma

(2015) Wafa Hassen et al.   Oncotarget

Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma

(2015) Prahlad V. Raninga et al.   Oncotarget

The 26S proteasome is a multifaceted target for anti-cancer therapies

(2015) Tatyana A. Grigoreva et al.   Oncotarget

Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites

(2015) Krishna C. Vallabhaneni et al.   Oncotarget

CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation

(2015) Aldo M. Roccaro et al.   Cell Reports

Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma

(2015) L. Hansmann et al.   Cancer Immunology Research

The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells

(2015) Mohamed-Amine Hamouda et al.   Oncotarget

INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support

(2015) Jun Li et al.   NEOPLASIA

A Single Nucleotide Polymorphism in SLC7A5 Is Associated with Gastrointestinal Toxicity after High-Dose Melphalan and Autologous Stem Cell Transplantation for Multiple Myeloma

(2014) Jennifer L. Giglia et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

TPL2 kinase regulates the inflammatory milieu of the myeloma niche

(2014) C. Hope et al.   BLOOD

Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells

(2014) J. Wang et al.   BLOOD

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

(2014) A. Spencer et al.   BLOOD

Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in -17p high risk disease

(2014) Klaus M. Kortüm et al.   BRITISH JOURNAL OF HAEMATOLOGY

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present

(2014) Mathew C Casimiro et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R

(2014) TING XIONG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma

(2014) H A F Stessman et al.   LEUKEMIA

Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

(2014) L Melchor et al.   LEUKEMIA

The role of P-glycoprotein in drug resistance in multiple myeloma

(2014) Joseph Abraham et al.   LEUKEMIA & LYMPHOMA

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

The role of epigenetics in the biology of multiple myeloma

(2014) K Dimopoulos et al.   Blood Cancer Journal

SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy

(2014) Aldo M. Roccaro et al.   Cell Reports

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma

(2014) P. J. Teoh et al.   Biomed Research International

Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1

(2013) Teresa S. Hawley et al.   AMERICAN JOURNAL OF HEMATOLOGY

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

(2013) J Moreaux et al.   BRITISH JOURNAL OF CANCER

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone

(2013) Daniel Heintel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers

(2013) Wen Zhou et al.   CANCER CELL

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

(2013) Robert O’Connor et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Non-genomic events determining the sensitivity of hemopoietic malignancies to glucocorticoid-induced apoptosis

(2013) Shlomit Kfir-Erenfeld et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in Multiple myeloma patients?

(2013) Ahmed M. L. Bedewy et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

(2013) B A Walker et al.   LEUKEMIA

IMWG consensus on risk stratification in multiple myeloma

(2013) W J Chng et al.   LEUKEMIA

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

(2013) J Chu et al.   LEUKEMIA

The clinical significance of cereblon expression in multiple myeloma

(2013) Steven R. Schuster et al.   LEUKEMIA RESEARCH

MTI-101 (Cyclized HYD1) Binds a CD44 Containing Complex and Induces Necrotic Cell Death in Multiple Myeloma

(2013) Anthony W. Gebhard et al.   MOLECULAR CANCER THERAPEUTICS

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model

(2013) H. A. F. Stessman et al.   MOLECULAR CANCER THERAPEUTICS

Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells

(2013) Hua Jiang et al.   Molecular Oncology

An Inverse Switch in DNA Base Excision and Strand Break Repair Contributes to Melphalan Resistance in Multiple Myeloma Cells

(2013) Mirta M. L. Sousa et al.   PLoS One

A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma

(2013) Tae-Hoon Chung et al.   PLoS One

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

Blockade of XBP1 splicing by inhibition of IRE1  is a promising therapeutic option in multiple myeloma

(2012) N. Mimura et al.   BLOOD

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

(2012) J. B. Egan et al.   BLOOD

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

(2012) Dharminder Chauhan et al.   CANCER CELL

Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate

(2012) Patrick S. Ward et al.   CANCER CELL

Pharmacogenomics Knowledge for Personalized Medicine

(2012) M Whirl-Carrillo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A gene expression signature for high-risk multiple myeloma

(2012) R Kuiper et al.   LEUKEMIA

How glucocorticoid receptors modulate the activity of other transcription factors: A scope beyond tethering

(2012) Dariusz Ratman et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors

(2012) J. Moreaux et al.   MOLECULAR CANCER THERAPEUTICS

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

(2011) J. D. Shaughnessy et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

(2011) J. A. Zonder et al.   BLOOD

Genetic variations in multiple myeloma II: association with effect of treatment

(2011) Annette Vangsted et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells

(2011) K A Monaghan et al.   LEUKEMIA

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

(2010) G. W. Xu et al.   BLOOD

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

(2010) A. Broyl et al.   BLOOD

PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors and potentiates TRAIL-mediated apoptosis in multiple myeloma cells

(2010) E N Maginn et al.   BRITISH JOURNAL OF CANCER

Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis

(2010) V. Kapuria et al.   CANCER RESEARCH

Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome

(2010) N. J. Dickens et al.   CLINICAL CANCER RESEARCH

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

(2010) J. Moreaux et al.   HAEMATOLOGICA

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

(2010) D. Hose et al.   HAEMATOLOGICA

Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1)

(2009) Beatriz Sánchez-Vega et al.   BRITISH JOURNAL OF HAEMATOLOGY

Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition

(2009) J. R. St-Germain et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome

(2008) Olivier Decaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

(2007) Y.-T. Tai et al.   BLOOD